https://immatics.com/: Immatics Presents Data Update on Dose Escalation from Ongoing ACTengine Cell Therapy Programs · cancer · Tumor shrinkage observed in 8 out of 10 patients including one partial response consistent with robust biological activity of infused T cell products · Houston, Texas and Tuebingen, Germany, March 17, 2021 - Immatics N.V.(NASDAQ: IMTX, "Immatics"), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced a clinical data update from the dose escalation cohorts of the company's ongoing Phase 1 trials for its engineered Adoptive Cell Therapy approach (also known as TCR-T). The treatment of patients with ACTengine product candidates IMA201, IMA202 and IMA203 at initial dose levels below one billion transduced cells, intended to establish safety and first biological activity, showed first anti-tumor activity with 9 out of 10 evaluable patients showing disease control as well as tumor shrinkage observed in 8 out of 10 patients including one partial response. Clinical observations were consistent with observed robust engraftment, persistence and tumor infiltration of infused ACTengine T cells. Overall, all product candidates demonstrated a manageable safety and tolerability profile. Each of the ACTengine product candidates harness the patient's own T cells, which are genetically engineered to express a novel, proprietary T cell receptor (TCR) directed against a defined cancer target.